Retatrutide (GLP-3R)

Retatrutide – Triple GIP/GLP‑1/Glucagon Receptor Agonist for Obesity and Metabolic Research

Retatrutide is a long‑acting synthetic peptide incretin mimetic that activates three key metabolic receptors: GIPR (gastric inhibitory polypeptide receptor), GLP‑1R (glucagon‑like peptide‑1 receptor), and GCGR (glucagon receptor). This multi‑pathway design enables concurrent modulation of appetite, glucose homeostasis, lipid metabolism, and energy expenditure, making retatrutide a leading candidate in experimental models of obesity and diabetes pharmacotherapy.

Key features

• Triple receptor agonism: Retatrutide combines potent GIP agonism with GLP‑1 and glucagon receptor activation, enhancing insulin secretion, reducing glucagon where appropriate, slowing gastric emptying, and increasing energy expenditure.

• Robust weight‑loss pharmacology: Across phase 2 and early phase 3 trials, once‑weekly retatrutide has produced large, dose‑dependent body‑weight reductions and improvements in glycemic control in adults with obesity, with or without type 2 diabetes.

• Long‑acting profile: With an approximate half‑life of about 6 days and time to peak levels within 12–72 hours, retatrutide is designed for convenient once‑weekly subcutaneous dosing in clinical research.

• Broad cardio‑metabolic potential: Ongoing and planned studies are evaluating impacts on liver steatosis, kidney function, cardiovascular risk, osteoarthritis symptoms, and other obesity‑related complications.

  
  

Research applications

Retatrutide is being studied in experimental and clinical‑adjacent settings focused on:

• Obesity and weight‑management pharmacotherapy, including dose‑response effects on percent weight loss, body‑composition changes, and weight‑maintenance strategies.

• Type 2 diabetes and dysglycemia, assessing HbA1c, fasting glucose, insulin sensitivity, and beta‑cell function under triple‑agonist incretin stimulation.

• Cardio‑renal and hepatic outcomes, such as nonalcoholic fatty liver disease, diabetic kidney disease, and cardiovascular events in high‑risk populations.

• Obesity‑related comorbidities (e.g., osteoarthritis), where reductions in body weight are linked to improvements in pain, function, and quality‑of‑life scores.

  
  

Recommended handling

• For controlled laboratory and research use only, by qualified professionals.

• Store in a cool, dry environment protected from light; follow institutional SOPs for peptide storage, reconstitution, aliquoting, and disposal.

• Investigators should consult current literature and protocol data for dose‑escalation schemes, target populations, and key endpoints (weight, HbA1c, cardio‑metabolic markers) appropriate to their model.

  
  

Important disclaimer

All compounds sold by Rocky Peptide Chain, including Retatrutide, are for research use only. They are not intended for human consumption, medical use, diagnostic purposes, or treatment of any disease or condition. No claims are made or implied regarding weight loss, diabetes control, cardio‑protection, or therapeutic benefit. Researchers are solely responsible for appropriate handling, experimental design, and compliance with all applicable regulations.